Phase I study of cisplatin analogue nedaplatin (254-S) and paclitaxel in patients with unresectable squamous cell carcinoma

被引：0
作者：
I Sekine
H Nokihara
A Horiike
N Yamamoto
H Kunitoh
Y Ohe
T Tamura
T Kodama
N Saijo
机构：
[1] National Cancer Center Hospital,Divisions of Internal Medicine and Thoracic Oncology
[2] Tsukiji 5-1-1,undefined
[3] Chuo-ku,undefined
来源：
British Journal of Cancer | 2004年 / 90卷
关键词：
squamous cell carcinoma; paclitaxel; nedaplatin; lung cancer;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
The recommended phase II dose of paclitaxel 180 mg m−2 given as a 3-h infusion followed by nedaplatin 100 mg m−2 in a 1-h infusion every 3–4 weeks was determined in 52 chemo-naive patients with unresectable squamous cell carcinoma (SCC), with a promising response rate for lung SCC of 55%.
引用
收藏
页码：1125 / 1128
页数：3
相关论文
共 50 条
  • [31] A Phase I/II Study of Second-Line Chemotherapy with Fractionated Docetaxel and Nedaplatin for 5-FU/Cisplatin-Resistant Esophageal Squamous Cell Carcinoma
    Akutsu, Yasunori
    Shuto, Kiyohiko
    Kono, Tsuguaki
    Uesato, Masaya
    Hoshino, Isamu
    Shiratori, Toru
    Miyazawa, Yukimasa
    Isozaki, Yuka
    Akanuma, Naoki
    Matsubara, Hisahiro
    HEPATO-GASTROENTEROLOGY, 2012, 59 (119) : 2095 - 2098
  • [32] Phase I trial of nedaplatin and paclitaxel for patients with non-small cell lung cancer
    Yoshiike, F
    Koizumi, T
    Kitaguchi, Y
    Hatayama, O
    Yasuo, M
    Sasabayashi, M
    Wakamatsu, H
    Fujimoto, K
    Kubo, K
    JOURNAL OF CHEMOTHERAPY, 2005, 17 (05) : 550 - 554
  • [33] Comparative study of cisplatin-based definitive concurrent chemoradiotherapy with S-1 versus paclitaxel for unresectable locally advanced esophageal squamous cell carcinoma
    Fang, Min
    Song, Tao
    Liang, Xiaodong
    Lv, Shiliang
    Li, Jianbo
    Xu, Hong'en
    Luo, Limin
    Jia, Yongshi
    ONCOTARGET, 2017, 8 (23) : 37080 - 37090
  • [34] Phase I study of the combination of nedaplatin and weekly paclitaxel in patients with advanced non-small cell lung cancer
    Okuda, Kentaro
    Hirose, Takashi
    Ishida, Hiroo
    Kusumoto, Sojiro
    Sugiyama, Tomohide
    Ando, Kohichi
    Shirai, Takao
    Ohnishi, Tsukasa
    Horichi, Naoya
    Ohmori, Tohru
    Adachi, Mitsuru
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2008, 61 (05) : 829 - 835
  • [35] Phase I study of the combination of nedaplatin and weekly paclitaxel in patients with advanced non-small cell lung cancer
    Kentaro Okuda
    Takashi Hirose
    Hiroo Ishida
    Sojiro Kusumoto
    Tomohide Sugiyama
    Kohichi Ando
    Takao Shirai
    Tsukasa Ohnishi
    Naoya Horichi
    Tohru Ohmori
    Mitsuru Adachi
    Cancer Chemotherapy and Pharmacology, 2008, 61 : 829 - 835
  • [36] Phase II and pharmacokinetic study of paclitaxel therapy for unresectable hepatocellular carcinoma patients
    Chao, Y
    Chan, WK
    Birkhofer, MJ
    Hu, OYP
    Wang, SS
    Huang, YS
    Liu, M
    Whang-Peng, J
    Chi, KH
    Lui, WY
    Lee, SD
    BRITISH JOURNAL OF CANCER, 1998, 78 (01) : 34 - 39
  • [37] Replacement of cisplatin with nedaplatin in a definitive 5-fluorouracil/cisplatin-based chemoradiotherapy in Japanese patients with esophageal squamous cell carcinoma
    Kuwahara, Akiko
    Yamamori, Motohiro
    Nishiguchi, Kohshi
    Okuno, Tatsuya
    Chayahara, Naoko
    Miki, Ikuya
    Tamura, Takao
    Inokuma, Tsubasa
    Takemoto, Yoshiji
    Nakamura, Tsutomu
    Kataoka, Kazusaburo
    Sakaeda, Toshiyuki
    INTERNATIONAL JOURNAL OF MEDICAL SCIENCES, 2009, 6 (06): : 305 - 311
  • [38] Phase II trial of neoadjuvant chemotherapy with docetaxel, nedaplatin, and S1 for advanced esophageal squamous cell carcinoma
    Tanaka, Yoshihiro
    Yoshida, Kazuhiro
    Tanahashi, Toshiyuki
    Okumura, Naoki
    Matsuhashi, Nobuhisa
    Yamaguchi, Kazuya
    CANCER SCIENCE, 2016, 107 (06): : 764 - 772
  • [39] Randomized Phase II Study to Comparing Docetaxel/Nedaplatin versus Docetaxel for 5-Fluorouracil/Cisplatin Resistant Esophageal Squamous Cell Carcinoma
    Yajima, Satoshi
    Suzuki, Takashi
    Nanami, Tatsuki
    Oshima, Yoko
    Kikuchi, Yoshinori
    Funahashi, Kimihiko
    Shimada, Hideaki
    ANNALS OF THORACIC AND CARDIOVASCULAR SURGERY, 2021, 27 (04) : 219 - 224
  • [40] Phase I/II study of nedaplatin and nab-paclitaxel for patients with previously untreated advanced squamous cell lung cancer: Kanto Respiratory Disease Study Group (KRSG) 1302
    Kasai, Takashi
    Mori, Kiyoshi
    Sugiyama, Tomohide
    Koyama, Nobuyuki
    Nakamura, Yoichi
    Ohyanagi, Fumiyoshi
    Fukuda, Hiroki
    Hoshi, Eishin
    Kobayashi, Kunihiko
    Nakayama, Mitsuo
    INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY, 2022, 27 (12) : 1841 - 1848
12345